Skip to main content
. 2023 Jan 31;4:3. doi: 10.21037/tbcr-23-2

Table 3. Treatment exposure.

Exposure Lapatinib + capecitabine (n=49) T-DM1 (n=151)
Lapatinib Capecitabine All-grade
Cycles received, n (%)
   ≤6 15 (30.6) 15 (30.6) 63 (41.7)
   7–12 21 (42.9) 21 (42.9) 53 (35.1)
   13–18 12 (24.5) 12 (24.5) 29 (19.2)
   19–24 1 (2.0) 1 (2.0) 5 (3.3)
   >24 0 0 1 (0.7)
Median treatment duration, months [range] 6.1 [1–14] 6.4 [1–14] 5.5 [0–17]

T-DM1, trastuzumab emtansine.